FDA rejects Eli Lilly's arthritis drug
Shares of Eli Lilly and partner Incyte drop after the U.S. Food and Drug Administration declines to approve a new drug for rheumatoid arthritis. Roselle Chen reports.
Advertisement
Recommended Stories
QuantumScape Making Big Moves: Time to Buy Before It Skyrockets?
The battery start-up might reach its ambitions sooner than expected.
Motley FoolMissed Out on Nvidia? This Incredibly Cheap Semiconductor Stock Is Crushing Nvidia in a Key Market Right Now, and It Could Soar 55%.
Nvidia hasn't been able to make much of a dent in the automotive chip market, but there is one company that's winning big in this space.
Motley Fool3 Magnificent S&P 500 Dividend Stocks Down 30% (or More) to Buy and Hold Forever
These three reliable dividend payers have historically high yields thanks to deep price declines.
Motley FoolAnthropic now lets kids use its AI tech -- within limits
AI startup Anthropic is changing its policies to allow minors to use its generative AI systems -- in certain circumstances, at least. Announced in a post on the company's official blog Friday, Anthropic will begin letting teens and preteens use third-party apps (but not its own apps, necessarily) powered by its AI models so long as the developers of those apps implement specific safety features and disclose to users which Anthropic technologies they're leveraging. In a support article, Anthropic lists several safety measures devs creating AI-powered apps for minors should include, like age verification systems, content moderation and filtering and educational resources on "safe and responsible" AI use for minors.
TechCrunchApple Says No Major App Developers Accept New Outside Payments
(Bloomberg) -- No major app developers have signed up to use outside payment options that Apple Inc. introduced earlier this year for its App Store because the fees they pay would be at least as high as they were before, according to testimony presented to a federal judge.Most Read from BloombergApple Nears Deal With OpenAI to Put ChatGPT on iPhoneIce Cube’s Big3 Basketball League Sells Its First Team in $10 Million DealFord Cuts Battery Orders as EV Losses Top $100,000 Per CarHow One Brooklyn N
BloombergMassive News for Intel Stock Investors
Intel was hit with more bad news that has enormous implications for investors.
Motley FoolBluesky now lets you personalize main Discover feed using new controls
Bluesky is now allowing users to personalize their main Discover feeds. The social network is rolling out an updated version of its app that lets users offer feedback about its algorithmic feed so they can better customize it using "Show more like this" and "Show less like this" buttons in a post's menu to choose which content the algorithm surfaces. The change will help Bluesky users create a timeline that takes into consideration their own preferences, not what the company thinks they should see.
TechCrunch40.2% of Warren Buffett's $362 Billion Portfolio Is Invested in 2 Artificial Intelligence (AI) Stocks
You won't catch Warren Buffett chasing the latest stock market trend, but many companies in Berkshire Hathaway's portfolio are benefiting from AI nonetheless.
Motley FoolBillionaire Bond King Bill Gross Says This 10% Ultra-High-Yield Dividend Stock Is "Best of the Bunch" For Pipeline Master Limited Partnerships
While the energy sector has gotten off to a hot start this year, opportunities in master limited partnerships (MLP) stick out from the crowd.
Motley FoolThis Is What the Latest Artificial Intelligence (AI) Earnings Reports Say About Nvidia Stock's Future
Intel and AMD's latest earnings reports make one thing clear about the state of Nvidia's competition in the AI chip market.
Motley Fool